Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer

Relative dose intensity (RDI) is a measurement of chemotherapy (CT) dose defined as the actual dose received divided by the standard calculated dose during a set period. The study objective was to assess the impact of a RDI ≥ 80% on response and survival of patients treated in first line CT by FOLFO...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2025-01, Vol.57 (1), p.30-37
Main Authors: Hoba, Julien, Grancher, Adrien, Hautefeuille, Vincent, Turpin, Anthony, Bouhier-Leporrier, Karine, Galais, Marie-Pierre, Bignon, Anne-Laure, Di Fiore, Aude, Desgrippes, Romain, Miglianico, Laurent, Avisse, Benoit, Baconnier, Mathieu, Lam, You-Heng, Dutherage, Marie, Sefrioui, David, Malicot, Karine Le, Phelip, Jean-Marc, Michel, Pierre, Gillibert, André, Di Fiore, Frédéric
Format: Article
Language:English
Subjects:
Chemotherapy
Colorectal cancer
Relative dose intensity
Survival
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Relative dose intensity (RDI) is a measurement of chemotherapy (CT) dose defined as the actual dose received divided by the standard calculated dose during a set period. The study objective was to assess the impact of a RDI ≥ 80% on response and survival of patients treated in first line CT by FOLFOXIRI or FOLFIRINOX ± Bevacizumab (BV) for an unresectable metastatic colorectal cancer (mCRC). It was a retrospective, non-interventional, multicenter study calculating RDI from the first cycles of CT to the first CT-scan evaluation (CT-scan1). Objective response and disease control rates (ORR and DCR), progression-free survival (PFS) and overall survival (OS) were compared between patients with RDI ≥ 80% and
ISSN:1590-8658
1878-3562
1878-3562
DOI:10.1016/j.dld.2024.05.014